Health-related outcomes and economic burden in Japan: focus on inflammatory bowel disease, multiple sclerosis, and depression

Abstract

Kaoru Yamabe Healthcare Policy and Access, Takeda Pharmaceutical Company Limited, Chuou-ku, Tokyo, JapanThis series presents articles using data collected from the National Health and Wellness Survey1 in Japan to assess the burden of inflammatory bowel disease (IBD), multiple sclerosis (MS), and depression using a common methodology involving cases vs. controls and patient-reported outcome measures (PROMs).  

Keywords

• NA